Would you consider the use of PARP inhibitors in patients with BARD 1 mutation and refractory pancreatic cancer?

I will use it.

In a disease like pancreatic adenocarcinoma, where treatment options are so limited, one has a much lower threshold to think out of the box. Of course there is no good (or any) data on the use of PARPi in this particular setting. However, with the manageable toxicity of the PARPi, I wo...